199 related articles for article (PubMed ID: 33751979)
1. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.
Ren C; Sun N; Kong Y; Qu X; Liu H; Zhong H; Song X; Yang X; Jiang B
Eur J Med Chem; 2021 May; 217():113335. PubMed ID: 33751979
[TBL] [Abstract][Full Text] [Related]
2. Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK).
Xie S; Sun Y; Liu Y; Li X; Li X; Zhong W; Zhan F; Zhu J; Yao H; Yang DH; Chen ZS; Xu J; Xu S
J Med Chem; 2021 Jul; 64(13):9120-9140. PubMed ID: 34176264
[TBL] [Abstract][Full Text] [Related]
3. Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation.
Wang H; Wang Y; Guo W; Du B; Huang X; Wu R; Yang B; Lin X; Wu Y
Drug Des Devel Ther; 2018; 12():1183-1193. PubMed ID: 29785088
[TBL] [Abstract][Full Text] [Related]
4. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.
Sun N; Ren C; Kong Y; Zhong H; Chen J; Li Y; Zhang J; Zhou Y; Qiu X; Lin H; Song X; Yang X; Jiang B
Eur J Med Chem; 2020 May; 193():112190. PubMed ID: 32179332
[TBL] [Abstract][Full Text] [Related]
5. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
[TBL] [Abstract][Full Text] [Related]
6. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
[TBL] [Abstract][Full Text] [Related]
8. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
9. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
Kim D; Koh Y; Yoon SS
Anticancer Res; 2020 Mar; 40(3):1395-1403. PubMed ID: 32132036
[TBL] [Abstract][Full Text] [Related]
11. Alectinib for advanced
Ly AC; Olin JL; Smith MB
Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a PROTAC targeting ALK with in vivo activity.
Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
[TBL] [Abstract][Full Text] [Related]
13. Alectinib for treatment of ALK-positive non-small-cell lung cancer.
Avrillon V; Pérol M
Future Oncol; 2017 Feb; 13(4):321-335. PubMed ID: 27780368
[TBL] [Abstract][Full Text] [Related]
14. Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
Funazo T; Tsuji T; Ozasa H; Furugaki K; Yoshimura Y; Oguri T; Ajimizu H; Yasuda Y; Nomizo T; Sakamori Y; Yoshida H; Kim YH; Hirai T
Mol Cancer Ther; 2020 Jun; 19(6):1320-1327. PubMed ID: 32217741
[TBL] [Abstract][Full Text] [Related]
15. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
[TBL] [Abstract][Full Text] [Related]
16. A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer.
Sharda S; Khandelwal R; Adhikary R; Sharma D; Majhi M; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(13):1129-1144. PubMed ID: 31109278
[TBL] [Abstract][Full Text] [Related]
17. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
18. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
[TBL] [Abstract][Full Text] [Related]
19. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
20. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
